Professor of Medicine
IHV, 725 West Lombard Street
Education and Training
Undergraduate: BS in Biology, University of North Carolina at Chapel Hill, NC
Graduate: MSPH in Epidemiology, University of Alabama at Birmingham School of Public Health, Birmimgham, AL
Medical School: LSU Medical Center, New Orleans, LA
Internship/Residency (Internal Medicine): LSU Medical Center, New Orleans, LA
Fellowship (Infectious Diseases): University of Alabama at Birmingham, AL
Dr. Baddley has an appointment at the Institute of Human Virology and the University of Maryland Stewart and Marlene Greenebaum Cancer Center (UMGCC). He recently joined our faculty in 2020, moving from the University of Alabama at Birmingham (UAB), where he was Professor of Medicine in the Division of Infectious Diseases. After receiving an undergraduate degree from the University of North Carolina at Chapel Hill, Dr. Baddley earned his medical degree from Louisiana State University (LSU) School of Medicine, New Orleans. He completed an internship and residency at LSU Medical Center and fellowship in infectious diseases at University of Alabama at Birmingham, where he was Chief Infectious Diseases Fellow. At UAB he served as Director, Transplant Infectious Diseases at UAB’s Comprehensive Transplant Institute and Director of the Infection Control Program at the Birmingham VA Medical Center.
Dr. Baddley’s clinical work focuses on prevention and management of infections in the immunocompromised host. He participates in outpatient clinic and inpatient consult services for solid organ transplant and cancer patients. Dr. Baddley has a part-time position at the Baltimore VA Hospital, where he is involved with Antimicrobial Stewardship and clinical work at the Infectious Diseases clinic.
Dr. Baddley’s research interests include clinical trials and outcomes research related to immunocompromised hosts. Ongoing areas of research include clinical trials of novel antifungal and CMV therapies, epidemiology of fungal infections, HIV transplantation and risk of infection and outcomes with use of biological therapies/immunomodulators.
Dr. Baddley currently serves as an Associate Editor of Open Forum Infectious Diseases and is on the ABIM’s Infectious Disease Exam Committee. He serves as co-chair of the education committee of the Mycoses Study Group Education and Research Consortium and as Secretary/Treasurer of the Transplant Infectious Diseases group of the Transplantation Society. He recently served as Chair, WHO Histoplasmosis Guidelines Development Group.
infections in transplant patients; infections is cancer patients; fungal infections; opportunistic infections; antimicrobial stewardship
CG Grijalva, L Chen, E Delzell, JW Baddley, T Beukelman, KL Winthrop, M Griffin, LJ Herrington, L Liu, R Ouellet-Hellstrom, N Patkar, DH Solomon, JD Lewis, F Xie, KG Saag, JR Curtis. Initiation of tumor necrosis factor-α antagonists and the risk of Hospitalization for infection in patients with autoimmune diseases. JAMA 2011;306 (21):2331-9.
D. Andes, N. Safdar, J. Baddley, G. Playford, J. Rex et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review from randomized trials. Clin Infect Dis 2012; 54(8); 1110-22.
J Zhang, F. Xie, E Delzell, L Chen, K Winthrop, JD Lewis, K Hayes, K Saag, JW Baddley, JR Curtis. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012;308(1);43-9.
Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, BeukelmanT, Patkar NM, Xie F, Nourjah P, Saag KG, Herrinton L, Solomon DH, Lewis JD, Ouellet-Hellstrom R, Curtis JR. Initiation of anti-TNF therapy is not associated with an increased risk of herpes zoster; from the Safety Assessment of Biologic ThERapy (SABER) Study. JAMA. 2013;309(9):887-895.
Locke JE, James NT, Mannon RB, Mehta SG, Pappas PG, Baddley JW, Desai NM, Montgomery RA, Segev DL. Imunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients. Transplantation 2014 Feb 27;97(4):446-50.
Baddley JW, Winthrop KL, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton L, Solomon DH, Lewis JD, Curtis JR. Non- viral opportunistic infections in new users of TNF inhibitor therapy: results of the Safety Assessment of Biologic ThERapy (SABER) Study. Ann Rheum Dis 2014 Nov;73(11):1942-8.
Winthrop KL, Novosad SA, Baddley JW, Calabrese L, Chiller T, Polgreen P, Bartalesi F, Lipman M, Mariette X, Lortholary O, Weinblatt M, Saag M, Smolen J. Opportunistic infections and biologic therapies in rheumatologic diseases: consensus recommendations for infection reporting during clinical trials and post-marketing surveillance. Submitted to Ann Rheum Dis 2015; Dec;74(12):2107-16.
Donnelly JP, Wang HE, Locke JE, Mannon RB, Safford MM, Baddley JW. Hospital-onset Clostridium difficle infection among solid organ transplant recipients. Am J Transplant 2015;15:2970-7.
JA Maertens, II Raad, KA Marr, TF Patterson, DP Kontoyiannis, OA Cornely, EJ Bow, G Rahav, D Neofytos, M Aoun, JW Baddley, M Giladi, WJ Heinz, R Herbrecht, W Hope, M Karthaus, D Lee, O Lortholary, VA Morrison, I Oren, D Selleslag,S Shoham, GR Thompson III, M Lee, R Maher, AH Schmitt-Hoffmann, B Zeiher, AJ Ullmann, M.D. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet 2016 Feb 20;387(10020);760-9.
JP Donnelly, JE Locke, PA MacLennan,G McGwin Jr., RB Mannon, MM Safford, JW Baddley, PM Muntner, HE Wang. Inpatient Mortality among Solid Organ Transplant Recipients Hospitalized for Sepsis and Severe Sepsis. Clin Infect Dis. 2016 Jul 15;63(2):186-94.
JP Donnelly, MM. Safford. NI Shapiro, JW Baddley, HE Wang. Application of the Third International Consensus Definitions for Sepsis (Sepsis-3) Classifications in a Population-based Cohort: The REasons for Geographic and Racial Differences in Stroke Study. Lancet Infect Dis. 2017 Jun;17(6)661-70.
Baddley JW, Cantini F, Goletti D, Gomez-Reino JJ, Mylonakis E, San-Juan R, Fernandez-Ruiz M, Torre-Cisneros J. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document: Safety of targeted and biological therapies: and Infectious Diseases perspective (section 2:Soluble immune effector molecules ; pro-inflammatory cytokines). Clin Microbiol Infect. 2018 Jun;24; S10-20.
Holland T, HW Boucher, I Raad, DJ Anderson, SE Cosgrove, S Aycock, JW Baddley, S Chow, VH Chu, et al. Riska, , ZA Rubin, ME Rupp, J Schrank Jr., M Sims, D Wray, MJ. Zervos, V Fowler Jr., MD, MHS1., Effect of an algorithm-Based therapy versus usual care on clinical success and serious adverse events in patients with staphylococcal bacteremia; a randomized,clinical trial. JAMA 2018 Sep 25;320(12):1249-1258.
Baddley JW, Forrest G. Cryptococcosis in Solid Organ Transplantation- Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice". Clin Transplant. 2019 Sep;33(9).
JP Donnelly, S Chen, CA Kauffman, P Verweij, A Groll, JW Baddley, T Sorrell, CJ Clancy,S Lockhart, W Steinbach, J Wingard, M Bassetti, H Akan, et al. Revision and update of the concensus definitions of invasive fungal disease from the European organization for research amd treatmemt of cancer and the mycoses study group education and research consortium. Clin Infect Dis 2019 Dec 5.
Zavala S, Baddley JW. Cryptococcus. Semin Respir Crit Care Med 2020:41(1);69-79.
In the News
Dr. Baddley was named as a "Best Doctor" by Birmingham Magazine and B-Metro Magazine from 2017-2020